A Study to Compare the Health Care Resource Utilization and Treatment Patterns in Patients With Actinic Keratosis Treated With Ingenol-Mebutate Versus Imiquimod, 5-Fluorouracil, Diclofenac Sodium And Methyl Aminolevulinate or Aminolevulinic Acid Photodynamic Therapy

Trial Profile

A Study to Compare the Health Care Resource Utilization and Treatment Patterns in Patients With Actinic Keratosis Treated With Ingenol-Mebutate Versus Imiquimod, 5-Fluorouracil, Diclofenac Sodium And Methyl Aminolevulinate or Aminolevulinic Acid Photodynamic Therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2016

At a glance

  • Drugs Ingenol mebutate (Primary) ; Aminolevulinic acid; Diclofenac; Fluorouracil; Imiquimod
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2016 New trial record
    • 01 Mar 2016 Results published in the Value in Health
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top